The CATT (Comparison of Age-related macular degeneration Treatments Trials) demonstrated equivalence between ranibizumab and bevacizumab for neovascular AMD. The key finding regarding dosing regimens was:
- A Monthly fixed dosing was superior to PRN dosing for both drugs in visual outcomes
- B PRN dosing was equivalent to monthly for ranibizumab but inferior for bevacizumab
- C Monthly ranibizumab was slightly superior to PRN ranibizumab; the two drugs were otherwise equivalent at 2 years ✓
- D Both monthly and PRN dosing were identical for both drugs at all time points
Correct answer: C. Monthly ranibizumab was slightly superior to PRN ranibizumab; the two drugs were otherwise equivalent at 2 years
Explanation
The CATT trial at 2 years found that monthly ranibizumab produced slightly better visual acuity outcomes than as-needed (PRN) ranibizumab, but the two drugs (ranibizumab and bevacizumab) were equivalent in efficacy when given on the same dosing schedule. This established bevacizumab as a cost-effective alternative to ranibizumab for neovascular AMD, significantly impacting global treatment guidelines and drug access.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.